# KHAN Technology Transfer Fund > KHAN Technology Transfer Fund is a VC fund in Dortmund backing Biotechnology and Medical. See 14 investments, check sizes, portfolio. Updated Aug 2026. - Type: VC Fund - Location: Dortmund, Germany - Total investments: 14 - Last investment: Mar 2026 - Lead investor: 50% - Last updated: Aug 2026 - LinkedIn: https://www.linkedin.com/company/khan-technology-transfer-fund-i/ - Website: https://khanu.de/ KHAN Technology Transfer Fund is a VC fund in Dortmund focused on Biotechnology and Medical. KHAN Technology Transfer Fund operates as an investment firm. ## Round sizes | Stage | Round size | | --- | --- | | Seed | $259k–$10M | | Series A | $5.6M–$10M | ## Investment focus ### Industry | Industry | Investments | Share | | --- | --- | --- | | Biotechnology | 5 | 36% | | Medical | 4 | 29% | | Biopharma | 2 | 14% | | Pharmaceutical | 2 | 14% | | Health Care | 1 | 7% | 7 industries tracked in total. ### Stage | Stage | Investments | Share | | --- | --- | --- | | Seed | 6 | 43% | | Pre-Seed | 1 | 7% | | Series A | 1 | 7% | | Venture - Series Unknown | 1 | 7% | ### Country | Country | Investments | Share | | --- | --- | --- | | Germany | 3 | 21% | | Austria | 1 | 7% | | Luxembourg | 1 | 7% | | Czech Republic | 1 | 7% | | United Kingdom | 1 | 7% | ## Investments | Company | Description | Amount | Stage | Date | Website | | --- | --- | --- | --- | --- | --- | | iDEL Therapeutics | iDEL Therapeutics is advancing a new class of cancer medicines by delivering therapeutic payloads directly into the cytosol of tumor cells through a unique, pan-cancer uptake mechanism. | $10.4M | Seed | Mar 17, 2026 | | | KyDo Therapeutics | KyDo Therapeutics is a biotechnology company that develops novel covalent-allosteric small molecule inhibitors. | $5.3M | Seed | Sep 16, 2025 | | | Casinvent Pharma | Casinvent Pharma develops new therapeutic options for the treatment of selected malignancies. | | Venture - Series Unknown | Jul 02, 2025 | | | Casinvent Pharma | Casinvent Pharma develops new therapeutic options for the treatment of selected malignancies. | | Venture - Series Unknown | Jul 02, 2025 | | | RIANA Therapeutics | RIANA Therapeutics is a spin-off from the University of Veterinary Medicine Vienna, developing first-in-class small-molecule inhibitors targeting oncogenic STAT5 signaling in Acute Myeloid Leukemia (AML). Our proprietary phenotypic screening platform enables identification of compounds selectively disrupting STAT5 oligomerization — a driver of AMLresistance — while preserving normal cell function. Having completed hit validation, RIANA is raising a seed round to advance to lead identification. Backed by non-dilutive funding. | $258.8K | Seed | Jan 01, 2025 | | | Casinvent Pharma | Casinvent Pharma develops new therapeutic options for the treatment of selected malignancies. | $1.7M | Seed | Jan 30, 2024 | | | Casinvent Pharma | Casinvent Pharma develops new therapeutic options for the treatment of selected malignancies. | $1.7M | Seed | Jan 30, 2024 | | | OrganoTherapeutics | OrganoTherapeutics use cutting-edge human-specific mini-brains for the discovery and development of effective drug candidates targeting Parkinson’s disease. We screen new molecules on our proprietary human-specific minibrains which represent a model mimicking faithfully the human Parkinson’s disease pathology. OrganoTherapeutics aims at developingnew drug candidates against Parkinson’s disease which are tested in state-of-the art 3D patient models. OrganoTherapeutics has developed first own proprietary drug candidates and has access to attractive libraries for further screening. | | Seed | Jul 26, 2023 | | | RIANA Therapeutics | RIANA Therapeutics is a spin-off from the University of Veterinary Medicine Vienna, developing first-in-class small-molecule inhibitors targeting oncogenic STAT5 signaling in Acute Myeloid Leukemia (AML). Our proprietary phenotypic screening platform enables identification of compounds selectively disrupting STAT5 oligomerization — a driver of AMLresistance — while preserving normal cell function. Having completed hit validation, RIANA is raising a seed round to advance to lead identification. Backed by non-dilutive funding. | $857.2K | Pre-Seed | Feb 08, 2023 | | | Nodus Oncology | Nodus Oncology Developing the DDR targeting therapies. | $2.9M | Seed | Feb 07, 2023 | | 10 of 14 investments shown. ## Co-investors - [i&i Biotech Fund](https://shizune.co/investors/profile/i-i-biotech-fund) — VC Fund, 5 deals together - [Holecek Family Foundation](https://shizune.co/investors/profile/hole%C4%8Dek-family-foundation) — VC Fund, 4 deals together - [i&i Prague](https://shizune.co/investors/profile/i-i-prague) — VC Fund, 4 deals together - [BIOINVESTIMED as](https://shizune.co/investors/profile/bioinvestimed-as) — VC Fund, 2 deals together - [Dynumerics as](https://shizune.co/investors/profile/dynumerics-as) — VC Fund, 2 deals together - [Garage Angels](https://shizune.co/investors/profile/garage-angels) — VC Fund, 2 deals together ## Similar investors ### Similar industry - [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund - [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund - [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund ### Similar stage - [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund - [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund - [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund ### Similar country - [Reflex Capital](https://shizune.co/investors/profile/reflex-capital) — VC Fund - [MITON](https://shizune.co/investors/profile/miton-cz-s-r-o) — VC Fund - [N1](https://shizune.co/investors/profile/nation-1) — VC Fund ## Featured in investor lists - [Medical Investors in Germany](https://shizune.co/investors/medical-investors-germany) - [Medical Investors in Czech Republic](https://shizune.co/investors/medical-investors-czech-republic) - [Medical VC Funds in Czech Republic](https://shizune.co/investors/medical-vc-funds-czech-republic) - [Health Care Investors in Czech Republic](https://shizune.co/investors/health-care-investors-czech-republic) - [Health Care VC Funds in Czech Republic](https://shizune.co/investors/health-care-vc-funds-czech-republic) - [All Investors in Czech Republic](https://shizune.co/investors/investors-czech-republic) ## FAQ ### What does KHAN Technology Transfer Fund invest in? KHAN Technology Transfer Fund invests primarily in Biotechnology, Medical and Biopharma startups, most often at Seed and Pre-Seed stage. Most of the 14 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio. ### What is KHAN Technology Transfer Fund's check size? KHAN Technology Transfer Fund typically joins rounds of $259k–$10M at Seed and $5.6M–$10M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds KHAN Technology Transfer Fund participates in. ### When did KHAN Technology Transfer Fund last invest? The most recent investment recorded for KHAN Technology Transfer Fund closed in Mar 2026. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly. ### Is Shizune's investor data accurate? Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page. # About Shizune Shizune.co is an investor database. Core features: - 48,091 startup investors (angels, VCs, accelerators, and others) - Email, phone, LinkedIn (for intros), socials, and other contact data - Updated daily from public funding news - CSV and Excel export The User can access the full database FOR FREE after signing up: shizune.co